Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Potential Link Between Industrial Pollutants and Acute Myeloid Leukemia Examined

March 8, 2019
By John Schieszer
News
Article

A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML.

Living in an industrial city with exposure to materials/pollution from industrial plants may be an important risk factor for developing acute myeloid leukemia (AML), according to a study published online in the journal Cancer.

Feras M. Ghazawi, MD, PhD, of the University of Ottawa in Ontario, Canada, and colleagues analyzed the incidence and geographic distribution of AML in Canada from 1992 to 2010 using three independent population‐based cancer registries. A total of 18,085 patients were identified during this timeframe, with an AML incidence of 30.61 cases per million individuals per year. The incidence and mortality rates were then examined at the levels of province/territory, city, and postal code.

Five industrial cities in Ontario had incidence rates that were significantly higher than the national average (Sarnia, Sault Ste. Marie, Thunder Bay, St. Catharines, and Hamilton). In one specific postal code in Sarnia, Ontario, the incidence rate was 106.81 cases per million individuals per year, which is more than three times higher than the national average.

“The pollution from local oil refineries and chemical plants in Sarnia may be implicated as a risk factor for AML in that city. Analysis of mortality rates at the province and city levels corroborated the findings from the incidence data,” concluded the authors.

Felipe Samaniego, MD, an associate professor of Lymphoma/Myeloma at MD Anderson Cancer Center in Houston, said this report independently reaches the conclusion that industry centers are associated with the emergence of a higher number of AML cases. However, in some ways it raises more questions than answers, he said.

“It is an area of immensely important and fruitful research. We now have the capacity to look at sum experiences of all studies that identify hotspots of cancers and analyze what is common to most areas that leads to a high incidence of AML,” Samaniego told Cancer Network. “The report implies that pollution is the culprit for AML; however, pollution may be only an associated factor and the real culprit is another factor associated with industry activity.”

Until now, several risk factors have been implicated in AML leukemogenesis, but the epidemiologic distribution and precise triggers for AML in Canada had not been fully investigated, the researchers noted.

Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
Related Content
Advertisement

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Tim Cortese
August 2nd 2025
Article

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

American Society for Transplantation and Cellular Therapy
July 30th 2025
Article

Researchers have found that donor age is a key determinant of outcomes in hematopoietic cell transplantation, with younger donors associated with significantly better survival and lower rates of GVHD.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL

Roman Fabbricatore
July 29th 2025
Article

AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.


Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.

FDA Accepts BLA, Grants Priority Review to Tab-Cel in EBV-Positive PTLD

Tim Cortese
July 28th 2025
Article

Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.

Related Content
Advertisement

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Tim Cortese
August 2nd 2025
Article

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

American Society for Transplantation and Cellular Therapy
July 30th 2025
Article

Researchers have found that donor age is a key determinant of outcomes in hematopoietic cell transplantation, with younger donors associated with significantly better survival and lower rates of GVHD.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.

sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL

Roman Fabbricatore
July 29th 2025
Article

AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.


Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.

FDA Accepts BLA, Grants Priority Review to Tab-Cel in EBV-Positive PTLD

Tim Cortese
July 28th 2025
Article

Following the lifting of a clinical hold, the FDA has again accepted the BLA for tabelecleucel in adult and pediatric patients with EBV-positive PTLD.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.